MSMengyao Song

Mengyao Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mengyao Song has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Percutaneous Transhepatic Retrieval of Dysfunctional Plastic Biliary Stents

    by Milan Sigdel, Chengzhi Zhang, Manoj Sigdel, Mikias Legesse Gebremedhin, Roshan Bhattarai, Xueliang Zhou, Mengyao Song, Kaihao Xu, Dechao Jiao

    Purpose: To evaluate the safety and efficacy of percutaneous transhepatic retrieval of dysfunctional plastic biliary stent (PBS). Materials and Methods: In this retrospective, single‐center study, clinical and procedural data of 36 patients who underwent percutaneous transhepatic retrieval of dysfunctional PBS between January 2015 and April 2021 were analyzed. The primary outcomes were technical success, clinical success, complications, procedure time, and radiation exposure. The secondary outcomes were biochemical indicators (total bilirubin [TB], direct bilirubin [DB], glutamic transaminase [ALT], and CA‐19‐9) measured before treatment and two weeks posttreatment. Results: Technical and clinical success were both 100%. Minor complications occurred in 4 cases (11.2%), including 3 hemobilia (Grade 1) and 1 mild cholangitis (Grade 2). The mean procedure time was 39.22 ± 9.34 minutes, with no statistical significance between benign and malignant disease groups ([40.52 ± 9.0] min vs. [38.91 ± 9.5], p = 0.68). The mean radiation exposure was 326.13 ± 206.06 mGy, with no statistical significance between benign and malignant groups ([353.64 ± 258.93] mGy vs. [319.49 ± 196.15] mGy, p > 0.75). Liver functions parameter improved significantly after 2 weeks (TB: [168.31 ± 53.07] vs. [41.70 ± 7.29] μmol/L, DB: [133.51 ± 46.42] vs. [25.39 ± 7.26] μmol/L, ALT: [94.67 ± 38.06] vs. [47.41 ± 13.69] U/L, and CA‐19‐9: [479.11 ± 160.14] vs. [150.72 ± 105.72] U/mL) (all p = 0.01). Conclusion: This study suggests that percutaneous transhepatic retrieval of dysfunctional PBS appears to be a safe and effective alternative when ERCP is not feasible. However, given the retrospective single‐center design, limited sample size, and short follow‐up, larger multicenter studies with longer observation are needed to validate these findings.

  • Open Access

    Clinical application of the retrograde track method in reopening dysfunctional biliary stents

    by Rongna Hou, Mengyao Song, Xueliang Zhou, Chengzhi Zhang, Dechao Jiao

    Background: Biliary stent dysfunction is challenging to treat in clinic. The retrograde track method (RTM) has a promising clinical application in the reopening of dysfunctional biliary stents. This study aimed to evaluate the clinical value of the RTM in reopening dysfunctional biliary stents. Methods: From February 2013 to January 2020, 151 patients underwent percutaneous transhepatic biliary interventional procedures for reopening dysfunctional biliary stents at the First Affiliated Hospital of Zhengzhou University, and 25 patients (12 females, 13 males; mean age 63.12 years old) underwent the RTM after anterograde reopening dysfunction biliary stent failure. Technical success, clinical success, irradiation dose, procedure time, complications, and overall survival (OS) were recorded, and levels of total bilirubin (TBIL), direct bilirubin (DB), alanine aminotransferase (ALT), albumin (ALB), and carbohydrate antigen-199 (CA-199) were compared before treatment and 1 month after treatment. Results: The technical and clinical success rates were 100% and 96%, respectively, and the irradiation dose and procedure times were 774.07±330.80 mGy and 45.16±9.48 min, respectively. Two patients (8%) experienced major complications. The median OS was 10.73 months [95% confidence interval (CI): 9.37–12.09]. Compared with pretreatment values, the mean levels at 1 month after RTM administration for TBIL (189.47±59.20 vs. 44.65±16.12 µmol/L), DB (144.21±55.83 vs. 27.95±13.86 µmol/L), ALT (89.62±30.85 vs. 49.44±14.25 U/L), and CA-199 (584.59±269.82 vs. 176.76±100.68 U/mL) showed significant decreases, while that of ALB (36.32±2.05 vs. 40.22±1.95 g/L) showed a significant increase (all P values Conclusions: RTM is an effective alternative treatment method when anterograde reopening of a dysfunctional biliary stent occurs.

  • Predicting early biliary infection after stenting of malignant biliary obstruction: model development and internal validation

    by Yiming Liu, Chengzhi Zhang, Mengyao Song, Xinwei Han, Dechao Jiao

    Purpose To analyze the risk factors and develop a clinical prediction model for early biliary infection (EBI) after percutaneous transhepatic biliary stenting (PTBS) in patients with malignant biliary obstruction (MBO). Methods The clinical data of 236 patients with MBO treated with PTBS from June 2012 to June 2021 were retrospectively analyzed. Independent risk factors were analyzed by univariate and multivariate logistic regression, and a nomogram model was constructed based on the results. Discrimination, calibration, and clinical usefulness of this model were further assessed. Results The technical success rate of PTBS was 100%, and EBI after PTBS was 20.3%. Multivariate logistic regression analysis showed that hilar MBO (P = 0.020), diabetes (P = 0.001), previous surgical or endoscopic intervention (P = 0.007), procedure time > 60 min (P = 0.007), and intraprocedural biliary hemorrhage (P = 0.003) were independent risk factors for EBI after PTBS. A nomogram model was developed to predict the probability of EBI. ROC curves showed good discrimination of the model (area under curve = 0.831). The calibration plot indicated that the predicted probability of EBI by this model was in good agreement with the actual probability of EBI. The DCA curves showed that the net benefit of nomogram-assisted decisions was higher than or equal to the net benefit of treatment for all or none at a wide threshold probability (0–0.8). Conclusion The nomogram model based on the above independent risk factors can predict the probability of EBI and model-assisted treatment decisions contribute to improved clinical outcome. Therefore, MBO patients with probability of EBI > 0.20 based on the model should be recommended for perioperative broad-spectrum antibiotics and close monitoring.


  • Celiac plexus block combined with 125I seeds for refractory epigastric pain from abdominal malignancies: a retrospective case–control study

    by Yiming Liu, Chengzhi Zhang, Mengyao Song, Kaihao Xu, Xinwei Han, Dechao Jiao

    Purpose To evaluate the clinical efficacy of celiac plexus block (CPB) combined with 125I seeds implantation (ISI) for refractory epigastric pain from abdominal malignancies. Methods The data of 81 patients with refractory epigastric pain [visual analog scale (VAS) score ≥ 4] from abdominal malignancies were collected in this retrospective case–control study. Group A (n = 40) was treated with CPB alone, while Group B (n = 41) underwent CPB combined with ISI. The primary study endpoints were the VAS score, quality of life (QoL), and local tumor control (LTC) rate. The secondary endpoints were complications, progression-free survival (PFS), and overall survival (OS). Results The VAS scores at week 2 (T2), week 4 (T4), week 8 (T8), and week 12 (T12) in both groups were significantly lower compared with the pretreatment values (all P < 0.01). VAS scores in Group B showed a sustained decrease, especially for “mild pain” and “moderate pain,” while the VAS scores in Group A rebounded at T8 and T12 (both P < 0.01). The QoL in Group B improved significantly from T4 until T12, which better than that at T12 in Group A (all P < 0.01). The LTC rates at T8 were 35.0% and 92.7% in Groups A and B, respectively, with a significant difference (P < 0.01). Group B had a slightly lower complication rate and a slightly longer median PFS/OS than group A, but neither was statistically different (P = 0.09 and P = 0.99, respectively). Conclusion CPB combined with ISI performs more sustained pain relief (up to 12 weeks) compared to CPB alone, and ultimately improves the patients’ QoL.